Maxim Group Downgrades Momenta Pharmaceuticals (MNTA) to Sell

September 7, 2016 7:04 AM EDT
Get Alerts MNTA Hot Sheet
Price: $14.35 -2.71%

Rating Summary:
    10 Buy, 3 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade MNTA Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Maxim Group downgraded Momenta Pharmaceuticals (NASDAQ: MNTA) from Hold to Sell with a price target of $6.00.

Analyst Jason McCarthy commented:

  • With Teva (TEVA-$51.33-Buy) markedly reducing the Copaxone opportunity through years of patent litigation, Momenta shifted focus towards biosimilars, particularly a biosimilar of Humira, which we believe was a goal outside the reach of the company, even with Baxalta (Shire) as a partner. Recall that Baxalta walked away from developing additional early stage biosimilars with Momenta, which were subsequently partnered to Mylan.
  • The race for biosimilar Humira could come down to IP. Dosing and formulation patents represent significant hurdles that could delay commercialization of Humira biosimilars for several companies, we believe, including Momenta and Amgen, until at least 2022. More specifically, we are referring to Humira patents protecting dosing ('135) and formulation ('157 and '158).
  • Amgen was already denied Inter-Partes Review (IPR) for '135. In addition, to our knowledge, Momenta and Amgen both use stabilizing agents called "surfactants" and "polyols" in their biosimilar formulations, which could infringe on AbbVie '157 and '158, two key patents that do not expire until 2022.
  • The only biosimilar player we are aware of that specifically developed a biosimilar for Humira with a strong focus on IP is Coherus Biosciences (CHRS - $30.03 - Buy). Coherus won IPR vs. AbbVie '135 and has patent-protected formulations that may not infringe on AbbVie '157 or '158, positioning a potential commercial launch in 2019, in our view.

For an analyst ratings summary and ratings history on Momenta Pharmaceuticals click here. For more ratings news on Momenta Pharmaceuticals click here.

Shares of Momenta Pharmaceuticals closed at $12.23 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Downgrades, Hot Downgrades

Related Entities

Maxim Group

Add Your Comment